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Background: The most recent Kidney Disease Outcomes Quality Initiative (KDOQI) guidelines recommend that the
order of preference for arteriovenous fistula (AVF) placement is the radial-cephalic primary AVF, followed by the
secondary brachiocephalic (BC) and, if either of these is not viable, then brachiobasilic (BB) AVF should be fashioned.
However, there is limited prospective data comparing technical and clinical outcomes of these two approaches. The
purpose of our study was to compare outcome, patency, and complication rates in these two autogenous upper arm AV
accesses.
Methods: Between December 2003 and and January 2007, patients (61 male, 39 female) who have lost more distal AVFs
were enrolled in the study. After preoperative duplex mapping, patients with patent both basilic and cephalic veins greater
than 3 mm of diameter were randomized into BCAVF and BBAVF groups, each group consisting of 50 patients. All
procedures were performed under local anesthesia as one-stage procedures. Follow-up data were prospectively collected.
Kaplan-Meier analysis was used to calculate primary and secondary patency rates. Univariate and multivariate Cox-
regression analysis was used to find risks for the occurrence of thrombosis.
Results: Baseline demographics, clinical characteristics, and preoperative history dialysis access were comparable between
groups with the exception of the fact that mean caliber of the basilic veins were larger (4.51 0.93 mm vs 3.90 0.1 mm;
P  .002). The mean duration of operation was significantly shorter in the BC group compared with the BB group (P <
.001). There was no significant difference in the thirty day mortality, wound complications, 24 hour thrombosis,
postoperative hemorrhage, maturation, and time to maturation between the groups. Mean follow-up was 43.2  1.8
months. Primary patency at 1 and 3 years of follow-up was 87% and 81% for the BC group and 86% and 73% for the BB
group (P  .7) Secondary patency at one and three year follow-up was 87% and 70% for the BC group and 88% and 71%
for the BB group, respectively (P .8). Twenty-eight patients (28%) in the BC (18 patients) and BB (10 patients) group
died with a patent fistula during the follow-up period (P  .18). Multivariate analysis revealed that use of dominant arm
increased the risk of fistula failure.
Conclusion: We conclude that brachiobasilic and brachiocephalic AVF are equally effective alternatives; however, a longer
and demanding operation with BB AVF construction should be considered. (J Vasc Surg 2009;49:171-7.)When forearm vessels are not suitable for arteriovenous
fistula (AVF) creation or when these accesses have failed,
the options for vascular access include brachial artery-
originated either autogenous vein or prosthetic graft con-
struction. Autogenous arteriovenous fistulas are known for
their better long-term patencies and lower complication
rates compared with prosthetic graft access.1-3 In the upper
arm, there are usually two autogenous av fistula options
available, including brachial cephalic arteriovenous fis-
tula (BCAVF) and brachial-basilic arteriovenous fistula
(BBAVF). Unlike other veins in the arm, the basilic vein
has the advantage that, being a deep vein, it is protected
from damage caused by previous venepuncture and is often
of good caliber. However, the basilic vein must be mobi-
lized and superficialized during fistula formation, thus in-
creasing the complexity of the procedure as well as compli-
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Vascular Surgery.doi:10.1016/j.jvs.2008.08.002cation rates.4,5 On the other hand, the cephalic vein is
superficial in most patients, which is easily damaged with
previous venepunctures, and surgical technique to create
BCAVF is relatively simple. However, there is no consensus
on which of these types of AVF is to be preferred. Although
autogenous brachial-basilic upper arm transpositions
(BVT) have been extensively utilized, there has been sig-
nificant disparity in published patency rates.6-9 Based on
published data, the most recent Kidney Disease Outcomes
Quality Initiative (KDOQI) guidelines recommend that
the order of preference for AVF placement is the radial-
cephalic AVF followed by the BCAVF and, if either of these
is not viable, then BBAVF should be fashioned.10 How-
ever, there is no evidence based on prospective randomized
trials to support this recommendation. We performed a
prospective randomized clinical trial between the BCAVF
and to BBAVF to address this problem. The purpose of our
study was to compare outcome, patency, and complication
rates in these two autogenous upper arm AV accesses.
METHODS
In this single center study, from December 2003 to
January 2007, all patients in which previous forearm AVF
had failed or in which creation of a forearm AVF was not
suitable were evaluated for entry into the study. The study
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formed consent was obtained from all patients.
Preoperative assessment. All patients in need of up-
per arm vascular access underwent clinical examination and
duplex scanning of the upper extremity. Clinical examina-
tion consisted of inspection and palpation of the vessels of
the arm, andmeasurement of brachial artery blood pressure
on both sides. Digital photopletismographic pressure was
also measured and digit/brachial index was calculated as a
measure of arm arterial circulation.1
Duplex scanning of the arteries and superficial veins was
performed according to a standard protocol by an experi-
enced vascular technician.1 Philips HDI 5000 SonoCT
scanners (Philips Medical Systems, Bothell, Wash) were
used with a 12-MHz linear array probe. The anteroposte-
rior internal diameter and flow characteristics of the bra-
chial artery were recorded. Ultrasound venous mapping is
performed with a tourniquet placed around the upper arm,
and all veins seen were evaluated for size and evidence of
scarring and thrombosis. The diameters of the cephalic and
basilica veins were measured using B-mode technique, and
the mean vein diameter as well as smallest diameter was
calculated with a proximal latex tourniquet. The axillary
and sublavian veins were examined to rule out outflow
obstruction. When clinical or duplex findings suggested
proximal vein obstruction, venography was obtained. Pref-
erence was given to the nondominant arm over the domi-
nant arm.
Exclusion criteria included: planned graft AV access
procedures, previous BBAVF or BCAVF, age younger than
18 years, less than three mm of diameter of the brachial
artery at the elbow, absence of radial or ulnar artery pulses,
less than three mm of diameter of the basilic and cephalic
veins in any location in the upper arm, and inability to
obtain patient consent. Obesity was not a criteria for exclu-
sion from the study. Patients with patent both basilic and
cephalic veins greater than three mm of diameter as well as
triphasic arterial inflow were randomly arranged to BCAVF
and BBAVF groups by computerized allocation.
Patients. During the study entry period, BBAVF or
BCAVF was performed in 205 patients. In the other 11
patients, radiocephalic AVF was planned initially, preclud-
ing their enrollment in the study. Of the 205 consecutive
planned BBAVF or BCAVF procedures, 105 patients were
excluded from enrollment because of absence of radial or
ulnar artery pulses (three patients), history of upper exter-
mity arterial intervention (one patient), enrollment in an-
other clinical trial (three patients), age younger than 18
years (three patients), refusal to participate (19 patients),
previous failed BB AVF (nine patients), previous failed BC
AVF (29 patients), or less then three mm at diameter of the
basilic or cephalic veins (38 patients).
One hundred patients met inclusion criteria, agreed to
enroll, and provided informed consent. In all patients,
preoperative evaluation showed that it was possible to
create either a BC AVF or a BB AVF. Fifty patients were
randomized to the BCAVF group and 50 patients were
randomized to the BBAVF group. The randomizationsequence was strictly adhered to, and no patients were
allowed to cross over.
Surgical procedure. All procedures were performed
under local anesthesia as one stage procedure. Prophylactic
antibiotic was not used. The surgical technique used repre-
sents a modification of previous technique.1 Brachial-
basilic arteriovenous fistulas were constructed by making
three skip longitudinal incisions at the medial side of the
upper arm to dissect the basilic vein. The lowest incision
was also used for exploration of the brachial artery and
construction of the anastomosis. Care was taken not to
injure the medial cutaneous nerve of the arm during vein
dissection. All branches of the vein were isolated, ligated,
and divided. The basilic vein was mobilized up to its
junction with the brachial vein and was transected at the
level of elbow. Then, without clamping, the vein was gently
dilated with a heparinized saline injection. An anterolateral
subdermal tunnel was created using a long clamp on the
anterior aspect of the arm. Subsequently, the basilic vein
was pulled through the tunnel and an end-to-side vein-to-
artery anastomosis was performed with a running 6-0
polypropylene suture with a limited arteriotomy of six to
seven mm. Additional care was taken to secure hemostasis
at the end of the procedure.
Brachial-cephalic arteriovenous fistulas were created by
making a transverse incision a just proximal to the elbow as
previously described elsewhere.11 The cephalic vein was
dissected free and transected at the level of elbow. Subse-
quently, the anastomosis was performed as described in
BBAVF. The systemic heparin was not used either intra- or
postoperatively.
Technical success was defined as the presence of an
palpable thrill on the fistula at completion of procedure and
24 hours postoperatively. AVF were allowed to mature for
a minimum of four weeks, and the decision when to use the
access for the first time was made by the senior author
(C.K.). Maturation was defined as the time until the pri-
mary fistula was suitable to allow successful cannulation.
Cannulation of the fistula was allowed after maturation,
approximately four to six weeks.
Follow-up. All patients were followed for at least 12
months after operation and follow-up was continued until
May 2008. Complications, patency, and interventions were
recorded for this period. Previously described criteria were
used for definition and staging of complications during
follow-up.12 Absence of pulse and thrill over the AVF by
palpation and oscultation were the clinical criteria for de-
tection of thrombosis.
Occluded fistula was either abandoned or reopened using
mechanical thrombectomy. Following thrombectomy, percu-
taneous transluminal angioplasty was attempted. An aneu-
rysm was defined as circumscribed dilatation, either fusiform
or saccular, of a vascular access more than twice of diameter of
the preceeding and following segments of access.13When the
aneurysm becomes rapidly enlarged, inflamed, or symp-
tomatic, then revision was undertaken to prevent rupture
and bleeding.
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ondary patency. The different patency rates were defined as
described by Sidawy et al.12 Primary patency was defined as
the interval from the time of fully functional access place-
ment until any intervention designed to maintain or re-
establish patency, access thrombosis, or the time of mea-
surement of patency. Secondary patency was defined as the
interval from the time of fully functional access placement
until access abandonment, thrombosis, or the time of pa-
tency measurement including intervening manipulations
designed to reestablish functionality in thrombosed access.
Statistical analysis. Data are presented as mean 
standard error of mean. Analyses were performed using the
SPSS 15.0 software package (SPSS Inc, Chicago, Ill). Com-
parisons between groups were made using Fisher’s exact
test for categorical variables and t test for continuous
variables. Patency rates were calculated with the Kaplan-
Meier analysis. The log-rank test (Mantel-Cox) was used to
compare the patencies for the two groups. Differences were
considered statistically significant when the P value was less
than .05. Univariate analysis was used to evaluate preoper-
ative and intraoperative variables for their association with
primary patency.
Univariate Cox-regression analysis was used to find
risks for the occurrence of thrombosis. Parameters with
P  .20 were included in a multivariate backwards Cox-
regression. In this multivariate regression, a P value of less
than .10 was considered statistically significant.
RESULTS
Demographic and clinical characteristics were compa-
rable between groups (Table I). A similar proportion of
AVFBC and AVFBB patients were undergoing hemodial-
ysis at the time of access construction either with tunnelled
or non-tunnelled catheters (Table II). AVF was the first
access procedure in 11 (22%) patients in BCAVF and seven
(14%) patients in BBAVF. Dominant arm was selected in
10 (20%) patients in BCAVF and nine (18%) patients in
BBAVF.
Table III summarizes vascular characteristics for both
groups. On average, basilica veins used for the BBAVF
group were larger than cephalic veins used for the BCAVF
group (4.51  0.93 mm vs 3.90  0.1 mm, respectively,
Table I. Demographics of patients with BBAVF and
BCAVF
BBAVF
(n  50)
BCAVF
(n  50) P
Male 26 (52%) 30 (60%) .15
Mean BMI 23.39 24.30 .280
Mean age (y) 54.66 54.78 .966
Diabetes 16 (32%) 12 (24%) .378
Hypertension 23 (46%) 32 (64%) .072
Smoking 6 (12%) 6 (12%) 1.0
BBAVF, brachial-basilic arteriovenous fistula; BCAVF, brachial-cephalic
arteriovenous fistula; BMI, body-mass index.P  .002). There was no significant difference in the meanipsilateral brachial arterial pressure, digit/brachial index,
and diameter of the brachial artery between groups.
All patients tolerated the procedures well. The mean
duration of operation was significantly shorter in the
BCAVF group compared with the BBAVF group (P 
.001). There was no intraoperative mortality. Maturation
rates and duration of maturation were comparable among
groups. We had seven patients whose AVF were never
maturated and therefore were not included in the func-
tional patency analysis. There was no significant difference
in the thirty day mortality, wound complications, 24 hour
thrombosis, or postoperative hemorrhage, between the
groups (Table IV). There was no clinically significant steal
syndrome. In total, 14 interventions were performed in
BCAVF and BBAVF groups to maintain secondary pa-
tency. Eighty-four percent of BC and 92% of BB required
no revisions (P  .5). During the study period, we had 22
thrombosed AVF, including four patients who had failure
of AVF to maturate. We were not able to determine the
cause of the 22 thrombosed AVFs. In 11 of these, surgical
thrombectomywas performed (three in failure tomaturate)
and in the rest of the patients, no further procedure was
done. In these 22 patients with thrombosed AVF, no
Table II. Fistula characteristics of patients with BBAVF
and BCAVF
BBAVF
(n  50)
BCAVF
(n  50) P
Location of AVF .8
Nondominant arm 41 (82%) 40 (80%)
Timing of AVF .23
3 months in advance of dialysis 3 (6%) 9 (18%)
1 month in advance of dialysis 4 (8%) 6 (12%)
Nontunneller catheter dialysis 41 (82%) 33 (66%)
Tunneler catheter dialysis 1 (2%) 2 (4%)
Previous access dialysis 1 (2%) 0
Previous vascular access .58
None 7 (14%) 11 (22%)
One procedure 25 (50%) 25 (50%)
Two procedures 12 (24%) 11 (22%)
Three or more procedures 6 (12%) 3 (6%)
AVF, arteriovenous fistula; BBAVF, brachial-basilic arteriovenous fistula;
BCAVF; brachial-cephalic arteriovenous fistula.
Table III. Vascular characteristics of patients with
BBAVF and BCAVF
BBAVF
(n  50)
BCAVF
(n  50) P
Diameter of the vein (mm) 4.51 ( 0.93) 3.94 ( 0.12) .002
Ipsilateral brachial arterial
pressure (mmHg) 140.9 ( 4.2) 148.6 ( 3.6) .13
DBI (Digit brachial index) 0.9 ( 0.02) 0.92 ( 0.03) .9
Diameter of brachial
artery (mm) 4.83 ( 1.1) 4.85 ( 1.1) .8
BBAVF, brachial-basilic arteriovenous fistula; BCAVF, brachial-cephalic
arteriovenous fistula.additional intervention was performed in 5 of 12 vs 6 of 10
BCA
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Except for early postoperative anastomotic revision in one
patient, we did not perform any surgical revision with or
without thrombectomy.
Patency and survival. Mean follow-up was 28  1.8
months. Primary patency at one and three years of
follow-up was 87% and 81% for the BCAVF group and 86%
and 73% for the BBAVF group (P  .7; Fig 1) Secondary
patency at one and three year follow-up was 87% and 70%
for the BCAVF group, and 88% and 71% for the BBAVF
group, respectively (P .8; Fig 2). There was no significant
difference in primary patency or secondary patency be-
tween the two treatment groups).
Twenty-eight patients (28%) in the BCAVF (18 pa-
tients) and BBAVF (10 patients) group died with a
patent fistula during the follow-up period (P  .18); 2
(2%) of which in the BCAVF group died within 1 month
after operation. Two (2%) additional patients died dur-
Table IV. Perioperative characteristics and complications
BBAVF
Duration of operation (mean) (min) 86.02
Postoperative revision
Maturation rate 48
Duration of maturation (mean) (day) 33.4
Complications
Wound infection 2
Bleeding 2
Aneurysm 3
Interventions
None
Only thrombectomy
Failed
Aneurysm repair
Thrombectomy  PTA
AVF, arteriovenous fistula; BBAVF, brachial-basilic arteriovenous fistula;
antecedent.
Fig 1. Primary patency rates of patients with brachiocephalic and
brachiobasilic arteriovenous fistula.ing follow-up with thrombosed BCAVF fistulas. Threepatients underwent successful kidney transplantation
during the follow-up period, 2 of which were in the
BCAVF group.
There was no difference between groups in terms of
survival. Survival rate for the BCAVF group was 39.52 
2.2 months vs 43.61  2.4 months in the BBAVF group
(P  .8) (Appendix, online only). Factors evaluated for
univariate analysis included age, gender, presence of diabe-
tes, height, weight, body mass index, status of dialysis,
hypertension, smoking, previous AVF, selection of AVF
extremity, arterial pressure on the AVF side, vessel size,
digit brachial index, AVF group, duration of procedure,
maturation, early and late complications, as well as reinter-
ventions. In univariate analysis, history of previous upper
arm access more than two times use of dominant arm, small
caliber vein, female gender, and prolonged time to matu-
ration had a significant negative impact on secondary pa-
tency. Multivariate analysis revealed that vein type was not
tients with BBAVF and BCAVF
50) BCAVF (n  50) P
.39) 44.68 ( 2.16) .001
1
45 (90) .4
.78) 39.4 ( 3.89) .14
.7
1 (2%)
1 (2%)
) 4 (7.8%)
42
6
5
1
1
VF, brachial-cephalic arteriovenous fistula; PTA, plasma thromboplastin
Fig 2. Secondary patency rates of patients with brachiocephalic
and brachiobasilic arteriovenous fistula.in pa
(n 
( 4
0
(96)
( 1
(4%)
(4%)
(6.1%
46
3
1
0
1associated with any difference in primary patency.Multivar-
JOURNAL OF VASCULAR SURGERY
Volume 49, Number 1 Koksoy et al 175iate analysis revealed that use of dominant arm increased
the risk of fistula failure (relative risk (RR) 5611, 95%
confidence interval (CI) 1,68-18,72, P  . 005). Both
univariate and multivariate analysis revealed that vein type
was not associated with any difference in patency (Table V).
DISCUSSION
Although the most recent National Kidney Foundation
Dialysis OutcomesQuality Initiative (NKF/DOQI) guide-
lines edition recommends utilization of BBAVF, there are
conflicting reports regarding its safety, usability, and pat-
ency.3,6,9,10,14 In addition, there are limited data from
randomized prospective studies in the literature, further
restricting its widespread application.6 In this prospective
randomized study, we compared the outcomes of BCAVF
and BBAVF in order to determine whether selecting one
type of vein is superior in terms of patency and complica-
tions. Our analysis revealed that there was no significant
difference between these procedures in terms of complica-
tion rates, patency, or the number and type of revisions
performed.
There are several theoretical advantages of selecting the
basilic vein over the cephalic vein when considering AVF
creation.6 Unlike other veins in the arm, the basilic vein is
naturally deep, protected from damage caused by previous
venepuncture, and has a larger diameter.9 On the other
hand, these anatomical advantages lead to a more demand-
ing, complex surgical dissection and prolong surgery. In
order to manage these technical factors, the procedure is
often performed under general anesthesia.5 This study
clearly indicates that the procedure could be performed
under local anesthesia without adverse consequences. In
addition, local anesthesia has known advantages in terms of
safety, length of hospitalization, and lower cost. Although
our results did not differ in terms of patency and major
complications between groups, we did not assess the qual-
ity of life and complications such as arm swelling and pain.
Therefore, less invasive BC AVF may be the procedure of
choice when both veins are available.
Furthermore, initial construction of BCAVF leaves
enough undissected brachial artery to allow the later place-
ment of a BBAVF. Placement of these upper arm fistulae
does not preclude future placement of an arteriovenous
grafts, should the AVF fail. Despite all proposed advantages
for BB AVF, we found no significant difference in patency
Table V. Factors affecting secondary patency after
univariate analysis
P Relative Risk
Female gender .18 1.8
Previous AVF  2 procedure .11 2.8
Dominant arm .09 2.4
Smaller vein size .08 1.6
Prolonged time to
maturation
.12 1rates between the two AVF types. Our secondary patencyrates at one and three year follow-up was 87% and 70% for
the BC group and 88% and 71% for the BB group, respec-
tively, which was slightly at the upper limits of the reported
literature. In a retrospective analysis of 190 patients with
upper arm AVF, Woo et al concluded that autogenous
BBAVF and transposed BCAVF have similar patency rates.9
They reported that primary and secondary patency rates
were 52% and 62% at five years for BBAVF and 40% and
46% at five years for BCAVF, respectively. In another study
reported by Fitzgerald et al, there were no significant
differences in outcomes between two AVFs.3 However,
higher one year patency rates for BCAVF and BBAVF were
reported by Ascher et al, 72% and 70%, respectively.14
Discrimination of a functional fistula from a fistula that is
working clinically but not achieving satisfactory dialysis
may also be an issue while reporting.12
Our study revealed that brachiobasilic and brachioce-
phalic AVF are also equally effective alternatives in terms of
maturation rates. Maturation rates were somewhat higher
with BBAVF (96%) compared with BCAVF (90%), but this
difference did not reach statistical significance. Interest-
ingly, two patients in which BBAVF failed to mature were
patients who died in the first month. On the other hand, in
four patients in which BCAVF failed to mature, two pa-
tients could not be catheterized, and one had an inflow
problem and one had an outflow problem that were cor-
rected surgically. The mean time (days) to maturation was
also shorter for basilic vein group; however, again, this
difference did not reach statistical significance (P  .14).
One explanation for our patency results being in the
upper range of the previously described rates (62% to 95%),
may be the result of strict inclusion criteria.15,16 During the
study period, we performed 216 upper arm autogenous
access procedures and less than 50% of patients met our
inclusion criteria. In other words, the results of this study
may be applicable to only approximately half of real life
patients. Additionally, on the basis of routine preoperative
duplex scanning criteria, veins deemed usable for fistulas
were all greater than 3.0 mm in diameter all the way to the
axillary vein. We strongly believe that, at preoperative map-
ping if a candidate vein having a segment less than 3.0 mm
of diameter is seen, this vein should not be fashioned an
upper arm fistula. Finally, all veins used had no evidence of
phlebitis or mechanical defects, such as adhesions, stenosis,
or strictures, which also prescribed use of the vein for fistula
creation. Certain patient characteristics and factors are re-
ported to be associated with poorer outcome in upper arm
AVFs: older age, female gender, obesity, previous vascular
access, peripheral vascular disease, and ipsilateral central
venous catheterisation.3,15,17,18 In our study, univariate
analysis showed that risk factors associated with poorer
patency rates to be female gender, previous AVFmore than
two procedure, use of dominant arm for fistula creation,
smaller vein size, and prolonged time to maturation. There
is controversial data in the literature regarding the effect of
gender on AVF patency. In the univariate analysis, female
gender was related with an almost two times greater AVF
failure rate, however, multivariate analysis failed to show
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ion, it is difficult to speculate on gender effect on AVF
patency with the given data. Gibson et al reported that
female gender was associated with a lower primary patency
rate; however, other studies failed to demonstrate similar
effect of gender on AVF patency.18,19 Older age has also
been reported to be associated with decreased AVF paten-
cy19,20 and age greater than 60 years has been noted to
correlate with diminished BBAVF maturation in one se-
ries.15 However, age was not related with poorer patency
rates in this study.
We did find that a history of more than two previous
access procedure may be linked to fistula failure in both
BBAVF and BCAVF, at least in univariate analysis (RR:
2.8). This may in part be due to deleterious effects of
surgery on arterial and venous anatomy and possibly other
poorly defined patient factors. Patients with multiple pre-
vious fistulas are also more likely to be exposed to frequent
upper extremity central venous catheterization attempts,
which may lead to central venous outflow obstruction
eventually leading to fistula failure.14,18 Vein size may also
be an important factor for fistula patency as it has been
previously proposed that larger vein size is associated with
better patency. Hill et al reported that at a mean follow-up
of eight months, the primary patency rate of AVFs in
patients with basilic vein diameters of four mm or more on
preoperative duplex ultrasonography was 80%, versus 50%
for those with vein diameters less than four mm.21 Our
analysis revealed that one mm decrease in vein diameter
increases the failure rate by 1.5 times. However, although
the basilic vein diameter was significantly larger, there was
no difference in patency rates between the groups.
There is an anticipated morbidity from BBAVF con-
struction that is associated with three different incisions and
dissection of the vein in the arm, usually to the proximity of
the axilla. However, in this study there were no significant
differences in postoperative complication rates between
groups (Table IV). We have also not experienced any early
thrombosis, which may be due to the fact that almost all of
the surgeries were performed by or under supervision of the
senior author (C.K.). Previous reports have clearly indi-
cated that the surgeon’s experience was an important de-
terminant in fistula success.22,23 Finally, high-output car-
diac failure is also another feared complication of upper arm
fistulas in this predisposed patient population. Increasing
access flows increases the cardiac load and may induce
cardiac failure in high-flow AVFs,24 but this complication
was not observed in our patients.
Although we did not use objective hemodynamic cri-
teria to define steal syndrome, we did not see any clinically
significant ischemic symptoms defined as moderate to
severe steal syndrome according to the criteria of Sidawy
et al.12 Steal syndrome has been found to bemore prevalent
with BBAVFs compared with brachiocephalic fistula, most
likely because of the larger diameter of the arterialized
vein.14 However, in another large series, there was no
difference in terms of complications including steal syn-
drome.3 In a prospective study, Keuter et al reported that29% of patients with brachial-basilic AVFs developed symp-
tomatic ischemia while 11% needed intervention within
one year after access creation.25 Several clinical predictors
for access associated hand ischemia have been described:
age, diabetes, hypertension, peripheral arterial obstructive
disease, coronary artery disease, female gender, history of
peripheral arterial reconstruction, and radial artery volume
flow.25-29Most probably the strict exclusion criteria used in
our study including less than three mm of diameter of the
brachial artery at the elbow, and absence of radial or ulnar
artery pulses, as well as absence of postroperative hemody-
namic measurements, reduced the incidence of moderate
to severe steal syndrome reported here.
In conclusion, BBAVF and BCAVF had comparable
complication rates and primary and secondary patency rates
at one and three years of follow up. Our data indicate that
patients who are not candidates for forearm AVF could be
offered upper arm AVF using either native veins with
equally effective results. The combination of careful preop-
erative mapping, adherence to strict patient selection crite-
ria, and meticulous surgery likely influenced these out-
comes. Thus, although construction of BBAVF is more
demanding and has a longer duration of operation, it may
safely be fashioned under local anesthesia yielding compa-
rable maturation, patency, and complication rates with
BCAVF. Further prospective randomized studies compar-
ing the two fistula types with prosthetic grafts may aid in
evaluating their relative efficacy in this group of compli-
cated patients.
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Kaplan-Meier primary patency
Case processing summary
Group
Total N N of Events Censored
N Percent N Percent
Brachiocephalic 45 9 36 80.0%
Brachiobasilic 48 9 39 81.3%
Overall 93 18 75 80.6%
Survival table
Group
Time Status
Cumulative proportion
surviving at the time
N of
cumulative events
N of
remaining cases
Estimate Std. error Estimate Std. error Estimate Std. error
Brachiocephalic
1 3,000 Thrombosed .977 .022 1 43
2 3,000 Patent — — 1 42
3 3,000 Patent — — 1 41
4 6,000 Thrombosed .953 .032 2 40
5 6,000 patent — — 2 39
6 8,000 thrombosed .929 .040 3 38
7 8,000 patent — — 3 37
8 10,000 patent — — 3 36
9 12,000 thrombosed .903 .046 4 35
10 12,000 patent — — 4 34
11 12,000 patent — — 4 33
12 15,000 thrombosed .876 .052 5 32
13 15,000 patent — — 5 31
14 17,000 patent — — 5 30
15 18,000 patent — — 5 29
16 19,000 thrombosed .846 .058 6 28
17 19,000 patent — — 6 27
18 24,000 patent — — 6 26
19 26,000 patent — — 6 25
20 26,000 patent — — 6 24
21 27,000 thrombosed .810 .066 7 23
22 28,000 patent — — 7 22
23 28,000 patent — — 7 21
24 28,000 patent — — 7 20
25 28,000 patent — — 7 19
26 29,000 patent — — 7 18
27 30,000 patent — — 7 17
28 31,000 patent — — 7 16
29 31,000 patent — — 7 15
30 33,000 patent — — 7 14
31 33,000 patent — — 7 13
32 33,000 patent — — 7 12
33 33,000 patent — — 7 11
34 36,000 patent — — 7 10
35 36,000 patent — — 7 9
36 37,000 patent — — 7 8
37 38,000 patent — — 7 7
38 38,000 patent — — 7 6
39 39,000 thrombosed .675 .135 8 5
40 40,000 patent — — 8 4
41 44,000 thrombosed .506 .178 9 3
42 45,000 patent — — 9 2
43 46,000 patent — — 9 1
44 47,000 patent — — 9 0
45
46
JOURNAL OF VASCULAR SURGERY
Volume 49, Number 1 Koksoy et al 177.e2Appendix. Continued.
Group
Time Status
Cumulative proportion
surviving at the time
N of
cumulative events
N of
remaining cases
Estimate Std. error Estimate Std. error Estimate Std. error
Brachiobasilic
1 6,000 thrombosed .978 .022 1 45
2 9,000 thrombosed .957 .030 2 44
3 9,000 patent — — 2 43
4 9,000 patent — — 2 42
5 10,000 thrombosed .934 .037 3 41
6 11,000 patent — — 3 40
7 12,000 thrombosed — — 4 39
8 12,000 thrombosed .887 .048 5 38
9 15,000 thrombosed .864 .052 6 37
10 15,000 patent — — 6 36
11 15,000 patent — — 6 35
12 16,000 patent — — 6 34
13 16,000 patent — — 6 33
14 17,000 patent — — 6 32
15 18,000 patent — — 6 31
16 18,000 patent — — 6 30
17 18,000 patent — — 6 29
18 18,000 patent — — 6 28
19 18,000 patent — — 6 27
20 19,000 patent — — 6 26
21 19,000 patent — — 6 25
22 22,000 patent — — 6 24
23 25,000 thrombosed .828 .061 7 23
24 26,000 patent — — 7 22
25 27,000 patent — — 7 21
26 27,000 patent — — 7 20
27 27,000 patent — — 7 19
28 28,000 patent — — 7 18
29 32,000 patent — — 7 17
30 33,000 thrombosed — — 8 16
31 33,000 thrombosed .730 .084 9 15
32 33,000 patent — — 9 14
33 34,000 patent — — 9 13
34 34,000 patent — — 9 12
35 34,000 patent — — 9 11
36 36,000 patent — — 9 10
37 39,000 patent — — 9 9
38 39,000 patent — — 9 8
39 39,000 patent — — 9 7
40 46,000 patent — — 9 6
41 47,000 patent — — 9 5
42 48,000 patent — — 9 4
43 49,000 patent — — 9 3
44 51,000 patent — — 9 2
45 52,000 patent — — 9 1
46 52,000 patent — — 9 0
Means and medians for survival time
Group
Meana Median
Estimate Std. error
95% Confidence
interval Estimate Std. error
95% Confidence
interval
Lower
bound
Upper
bound
Lower
bound
Upper
bound
Lower
bound
Upper
bound
Lower
bound
Upper
bound
Brachiocephalic 39,153 2,271 34,701 43,605 — — — —
Brachiobasilic 43,556 2,480 38,695 48,416 — — — —
Overall 42,963 1,854 39,330 46,597 — — — —aEstimation is limited to the largest survival time if it is censored.
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2 Degrees of Freedom Significance
Log rank (Mantel-Cox) .084 1 .772
Test of equality of survival distributions for the different levels of group.
Kaplan-Meier secondary patency
Case processing summary
Group
Total N N of events Censored
N Percent N Percent
Brachiocephalic 45 9 36 80.0%
Brachiobasilic 48 9 39 81.3%
Overall 93 18 75 80.6%
Survival table
Group
Time Status
Cumulative proportion
surviving at the time
N of
cumulative events
N of
remaining cases
Estimate Std. error Estimate Std. error Estimate Std. error
Brachiocephalic
1 4,000 thrombosed .976 .024 1 41
2 6,000 thrombosed .952 .033 2 40
3 6,000 patent — — 2 39
4 8,000 thrombosed .928 .040 3 38
5 8,000 patent — — 3 37
6 10,000 patent — — 3 36
7 12,000 patent — — 3 35
8 12,000 patent — — 3 34
9 15,000 thrombosed — — 4 33
10 15,000 thrombosed .873 .053 5 32
11 15,000 patent — — 5 31
12 17,000 patent — — 5 30
13 18,000 patent — — 5 29
14 19,000 thrombosed .843 .059 6 28
15 19,000 patent — — 6 27
16 24,000 patent — — 6 26
17 26,000 patent — — 6 25
18 26,000 patent — — 6 24
19 27,000 thrombosed .808 .066 7 23
20 28,000 patent — — 7 22
21 28,000 patent — — 7 21
22 28,000 patent — — 7 20
23 28,000 patent — — 7 19
24 29,000 patent — — 7 18
25 31,000 patent — — 7 17
26 31,000 patent — — 7 16
27 33,000 patent — — 7 15
28 33,000 patent — — 7 14
29 33,000 patent — — 7 13
30 33,000 patent — — 7 12
31 36,000 patent — — 7 11
32 36,000 patent — — 7 10
33 37,000 patent — — 7 9
34 38,000 patent — — 7 8
35 39,000 thrombosed .707 .111 8 7
36 39,000 patent — — 8 6
37 40,000 patent — — 8 5
38 44,000 thrombosed .566 .155 9 4
39 45,000 patent — — 9 3
40 46,000 patent — — 9 2
41 46,000 patent — — 9 1
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Group
Time Status
Cumulative proportion
surviving at the time
N of
cumulative events
N of
remaining cases
Estimate Std. error Estimate Std. error Estimate Std. error
42 47,000 patent — — 9 0
43
44
45
46
Brachiobasilic
1 6,000 thrombosed .978 .022 1 45
2 9,000 patent — — 1 44
3 9,000 patent — — 1 43
4 10,000 thrombosed .956 .031 2 42
5 11,000 patent — — 2 41
6 12,000 thrombosed — — 3 40
7 12,000 thrombosed .909 .043 4 39
8 15,000 thrombosed .886 .048 5 38
9 15,000 patent — — 5 37
10 15,000 patent — — 5 36
11 16,000 patent — — 5 35
12 16,000 patent — — 5 34
13 17,000 patent — — 5 33
14 18,000 patent — — 5 32
15 18,000 patent — — 5 31
16 18,000 patent — — 5 30
17 18,000 patent — — 5 29
18 18,000 patent — — 5 28
19 19,000 patent — — 5 27
20 19,000 patent — — 5 26
21 22,000 patent — — 5 25
22 25,000 thrombosed .850 .058 6 24
23 26,000 thrombosed .815 .065 7 23
24 26,000 patent — — 7 22
25 27,000 patent — — 7 21
26 27,000 patent — — 7 20
27 27,000 patent — — 7 19
28 28,000 patent — — 7 18
29 32,000 patent — — 7 17
30 33,000 thrombosed — — 8 16
31 33,000 thrombosed .719 .086 9 15
32 33,000 patent — — 9 14
33 34,000 patent — — 9 13
34 34,000 patent — — 9 12
35 34,000 patent — — 9 11
36 36,000 patent — — 9 10
37 39,000 patent — — 9 9
38 39,000 patent — — 9 8
39 39,000 patent — — 9 7
40 46,000 patent — — 9 6
41 47,000 patent — — 9 5
42 48,000 patent — — 9 4
43 49,000 patent — — 9 3
44 51,000 patent — — 9 2
45 52,000 patent — — 9 1
46 52,000 patent — — 9 0
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Group
Meana Median
Estimate Std. error
95% Confidence
interval Estimate Std. error
95% Confidence
interval
Lower
bound
Upper
bound
Lower
bound
Upper
bound
Lower
bound
Upper
bound
Lower
bound
Upper
bound
Brachiocephalic 39,523 2,208 35,194 43,851 — — — —
Brachiobasilic 43,619 2,443 38,830 48,408 — — — —
Overall 43,209 1,802 39,677 46,740 — — — —
aEstimation is limited to the largest survival time if it is censored.
Overall comparisons
2 Degrees of freedom Significance
Log rank (Mantel-Cox) .044 1 .834
Test of equality of survival distributions for the different levels of group.
